TPTX - Week In Review: Ocumension Climbs To $2.5 Billion Market Cap After $184 Million Hong Kong IPO
Deals and Financings
Ocumension [HK:1477], a Shanghai ophthalmic pharma, completed a $184 million Hong Kong IPO and climbed 152% in its first trading session, giving the company a valuation of about $2.5 billion (see story). Founded in 2017, Ocumension was incubated by 6 Dimensions Capital and now has built a portfolio of 16 ophthalmology drugs for China development, mainly through in-licensings. The portfolio includes three assets at or near clinical stage, and five candidates in preclinical development. The company has raised $200 million in venture capital, including a $180 million B round one year